Cargando…

Energy intake as a short‐term biomarker for weight loss in adults with obesity receiving liraglutide: A randomized trial

BACKGROUND AND OBJECTIVE: Obesity is a chronic disease associated with many serious comorbidities. Pharmacologic therapies are approved for the treatment of obesity; however, short‐term biomarkers to predict weight loss are not well understood. This study aimed to determine the ability of single‐mea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saxena, Aditi R., Banerjee, Anindita, Corbin, Karen D., Parsons, Stephanie A., Smith, Steven R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170575/ https://www.ncbi.nlm.nih.gov/pubmed/34123395 http://dx.doi.org/10.1002/osp4.486

Ejemplares similares

The efficacy of liraglutide combined with intragastric balloon on weight loss
por: Yilmaz, Ahmet, et al.
Publicado: (2023)

Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review
por: Xie, Zeyu, et al.
Publicado: (2022)

Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults
por: Lean, M E J, et al.
Publicado: (2014)

Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin
por: Jensterle Sever, Mojca, et al.
Publicado: (2014)

Degree of obesity and gastrointestinal adverse reactions influence the weight loss effect of liraglutide in overweight or obese patients with type 2 diabetes
por: Zhou, Fang, et al.
Publicado: (2023)

Short-term monotherapy with Liraglutide for weight management: A case study
por: Almarshad, Feras
Publicado: (2019)

Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real‐world effectiveness study in Canada
por: Wharton, Sean, et al.
Publicado: (2020)

Marked weight loss on liraglutide 3.0 mg: Real‐life experience of a Swiss cohort with obesity
por: Santini, Sara, et al.
Publicado: (2022)

A Study on Weight Loss Cause as per the Side Effect of Liraglutide
por: Yu, Jin, et al.
Publicado: (2022)

Case Report: Liraglutide for Weight Management in Beckwith-Wiedemann Syndromic Obesity
por: Caputo, Marina, et al.
Publicado: (2021)

Liraglutide for Weight Management in Children and Adolescents With Prader–Willi Syndrome and Obesity
por: Diene, Gwenaëlle, et al.
Publicado: (2022)

The role of adjuvant pharmacotherapy with liraglutide for patients with inadequate weight loss following bariatric surgery
por: Colbourne, James R. M., et al.
Publicado: (2023)

Resting energy expenditure depends on energy intake during weight loss in people with obesity: a retrospective cohort study
por: Handa, Tomoko, et al.
Publicado: (2022)

The Effect of Liraglutide on Weight Loss in Women with Polycystic Ovary Syndrome: An Observational Study
por: Rasmussen, Christina B., et al.
Publicado: (2014)

The potent synergistic effects of the combination of liraglutide and canagliflozin on glycemic control and weight loss
por: Bell, David S.H.
Publicado: (2014)

Early Weight Loss with Liraglutide 3.0 mg Predicts 1‐Year Weight Loss and is Associated with Improvements in Clinical Markers
por: Fujioka, Ken, et al.
Publicado: (2016)

Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes
por: Hansen, Christian Stevns, et al.
Publicado: (2019)

Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial
por: Jensterle, Mojca, et al.
Publicado: (2017)

Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study
por: JENSTERLE, MOJCA, et al.
Publicado: (2016)

Intermittent energy restriction for weight loss: Spontaneous reduction of energy intake on unrestricted days
por: Harvey, Jennifer, et al.
Publicado: (2018)

Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study
por: Jensterle, Mojca, et al.
Publicado: (2015)

Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post‐bariatric surgery
por: Wharton, Sean, et al.
Publicado: (2019)

Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery
por: Muratori, Fabrizio, et al.
Publicado: (2022)

Assessing the adequacy of essential nutrient intake in obese dogs undergoing energy restriction for weight loss: a cohort study
por: German, Alexander J., et al.
Publicado: (2015)

Dietary intake of amino acids and vitamins compared to NRC requirements in obese cats undergoing energy restriction for weight loss
por: Grant, Caitlin E., et al.
Publicado: (2020)

GDF15 acts synergistically with liraglutide but is not necessary for the weight loss induced by bariatric surgery in mice
por: Frikke-Schmidt, Henriette, et al.
Publicado: (2019)

The relationship between resting energy expenditure and thyroid hormones in response to short-term weight loss in severe obesity
por: Marzullo, Paolo, et al.
Publicado: (2018)

Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss †
por: Simeone, Paola, et al.
Publicado: (2018)

Sustained self-regulation of energy intake. Loss of weight in overweight subjects. Maintenance of weight in normal-weight subjects
por: Ciampolini, Mario, et al.
Publicado: (2010)

Training response inhibition to food is associated with weight loss and reduced energy intake
por: Lawrence, Natalia S., et al.
Publicado: (2015)

Successful rapid weight reduction and the use of liraglutide for morbid obesity in adolescent Prader-Willi syndrome
por: Kim, Yoo-Mi, et al.
Publicado: (2020)

OR33-01 Liraglutide for Weight Management in Pubertal Adolescents with Obesity: A Randomized Controlled Trial
por: Kelly, Aaron S, et al.
Publicado: (2020)

Efficacy and safety of liraglutide in Indian adolescents with obesity
por: Kochar, I. S., et al.
Publicado: (2019)

Clinical Impact of Liraglutide as a Treatment of Obesity
por: Alruwaili, Heshma, et al.
Publicado: (2021)

Liraglutide pharmacokinetics and exposure‐response in adolescents with obesity
por: Carlsson Petri, Kristin C., et al.
Publicado: (2021)

Clinical and Genetic Predictors of Glycemic Control and Weight Loss Response to Liraglutide in Patients with Type 2 Diabetes
por: Kyriakidou, Artemis, et al.
Publicado: (2022)

Energy requirements during weight loss and weight maintenance of two morbidly obese cats
por: Corbee, Ronald Jan
Publicado: (2015)

Liraglutide for weight management: a critical review of the evidence
por: Mehta, A., et al.
Publicado: (2016)

The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients
por: Albaker, Waleed, et al.
Publicado: (2021)

Novel Molecules Regulating Energy Homeostasis: Physiology and Regulation by Macronutrient Intake and Weight Loss
por: Gavrieli, Anna, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_duglisfus6o32tb2ostvts74t7